

2/10/99

510(k) Premarket Notification - Original Submission  
Medlite™ Laser Systems Continuum Biomedical  
August 31, 1998

---

K983054

**510(k) Summary**

Submitter: Continuum Biomedical  
A Medical Division of Continuum Electro-Optics, Inc.  
6533 Sierra Lane  
Dublin, CA 94568  
Phone: (925) 828-3210  
Fax: (925) 556-2222

Contact: Laurie A. Ridener  
Regulatory Affairs Officer

Date Summary Prepared: August 31, 1998

Device Trade Name: Medlite™ Q-Switched Nd:YAG Laser  
Medlite™ IV Q-Switched Nd:YAG Laser

Common Name: Medical laser system

Classification Name: Instrument, surgical, powered, laser  
79-GEX  
21 CRF 878.48

Equivalent Device: Medlite™ Q-Switched Nd:YAG Laser, Medlite™ IV Q-Switched  
Nd:YAG Laser (K973719, SE date 12/23/97)  
ThermoLase LT-100 Nd:YAG Laser Hair Removal System  
(K950019, SE Date 04-03-95)

Intended Use: For the removal or lightening of unwanted hair without adjuvant  
preparation

Comparison: Equivalent

Nonclinical Performance Data: None

Clinical Performance Data: Clinical data was provided to support the use of the Medlite™ Q-  
Switched Nd:YAG Laser Systems without preparatory lotion to safely  
remove or lighten unwanted hair without adverse clinical findings.

Additional Information: None requested at this time



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

FEB 10 1999

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Ms. Laurie A. Ridener  
Regulatory Affairs Officer  
Continuum Biomedical  
6533 Sierra Lane  
Dublin, California 94568

Re: K983054  
Trade Name: Medlite™ Q-Switched Nd:YAG Laser  
Medlite™ IV Q-Switched Nd:YAG Laser  
Regulatory Class: II  
Product Code: GEX  
Dated: December 3, 1998  
Received: December 4, 1998

Dear Ms. Ridener:


We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4595. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsmamain.html>".

Sincerely yours,

A handwritten signature in black ink, appearing to read 'C. Witten', is written over the printed name.

Celia M. Witten, Ph.D., M.D.  
Director  
Division of General and  
Restorative Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

510(k) Premarket Notification - Original Submission  
Medlite™ Laser Systems Continuum Biomedical  
Revised February 5, 1999

---

Page 1 of 1

510(k) Number (if known): K983054

Device Name: Medlite™ Q-Switched Nd:YAG Laser  
Medlite™ IV Q-Switched Nd:YAG Laser

Indications for Use: For the removal or lightening of unwanted hair in the 1064nm mode only without adjuvant preparation using one or two treatments.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

  
(Division Sign-Off)

Division of General Restorative Devices

510(k) Number

K983054

Prescription Use X  
(Per 21 CFR 801.109)

OR

Over-the-Counter Use \_\_\_\_\_

(Optional Format 1-2-96)